{"id":834748,"date":"2025-04-07T18:46:33","date_gmt":"2025-04-07T22:46:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/"},"modified":"2025-04-07T18:46:33","modified_gmt":"2025-04-07T22:46:33","slug":"investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/","title":{"rendered":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, April  07, 2025  (GLOBE NEWSWIRE) &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against:<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Akero Therapeutics, Inc. (&#8220;Akero&#8221;) (<\/u><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TnxUp5yorpSKQmlIKGnbntzrBlZ0s_PHZ_wCXCb8aFLKAJEE4kD3fOQRoEjTl3tR5WEuQvovh0aFguNiWYP8ww==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>NASDAQ:AKRO<\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <u>)<\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Shareholders should email <a href=\"mailto:Fletcher@fmoorelaw.com\" rel=\"nofollow\" target=\"_blank\">Fletcher@fmoorelaw.com<\/a>; please contact only if shares acquired before <strong><u>September 13, 2022<\/u><\/strong><\/li>\n<\/ul>\n<p>The investigation concerns misrepresentations to investors as to the true nature of the patient population that was being tested in Akero&#8217;s SYMMETRY study. Specifically, despite telling investors that the study&#8217;s patient population was limited to those with NASH induced cirrhosis (a fact that was key for data integrity and the likelihood of study success), for approximately 20% of those being tested Akero had not confirmed that the patients had NASH and that NASH had in fact caused their cirrhosis.<\/p>\n<p>Akero shocked the market on October 10, 2023 when the company posted disappointing interim data from its Phase 2b SYMMETRY trial for EFX. Specifically, Akero stated that 22% (28mg) and 24% (50mg) of those on EFX and 14% on placebo indicated at least one stage improvement in fibrosis with no worsening of NASH at week 36, the trial&#8217;s primary endpoint, but that these changes were not statistically significant. In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events. On this news, Akero&#8217;s stock price fell $30.39 per share, or 62.61%, to close at $18.15 per share on October 10, 2023.<\/p>\n<p align=\"justify\">If you own Akero Therapeutics, Inc. (&#8220;Akero&#8221;) (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TnxUp5yorpSKQmlIKGnbnkVsBKus5-LYvg3fb_6-N-aIkLFER4PmPKLwInKKEvuEt6lbmb7g0p9STbpXVg0SAQ==\" rel=\"nofollow\" target=\"_blank\">NASDAQ:AKRO<\/a>), please contact\u00a0Fletcher Moore by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gKOEnlOR2t4sNy9u_izxEbG4PVa-M3jvYcnrB5yV2RKSUtbidF4tEUFz8n7JFM92hEd9KXfXRfQX18GV2SJ47vp49Gf7HsjsBWbLgmoxxg=\" rel=\"nofollow\" target=\"_blank\">fletcher@fmoorelaw.com<\/a> or (212) 709-8245.<\/p>\n<p align=\"justify\">You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. <strong><em>All representation is on a contingency fee basis. Shareholders pay no fees or expenses.<\/em><\/strong><\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">MOORE LAW PLLC<br \/>30 Wall Street, 8<sup>th<\/sup> Floor<br \/>New York, NY 10005<br \/>(212) 709-8245<br \/><a href=\"mailto:fletcher@fmoorelaw.com\" rel=\"nofollow\" target=\"_blank\">fletcher@fmoorelaw.com<\/a><br \/>www.fmoorelaw.com<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzMwMjJhZmUtY2E3NS00MzU1LWJhYzUtZDU0MTM2ODQ3Y2MyLTEzMDMwMTUtMjAyNS0wNC0wNy1lbg==\/tiny\/Moore-Law-PLLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. (&#8220;Akero&#8221;) ( NASDAQ:AKRO ) Shareholders should email Fletcher@fmoorelaw.com; please contact only if shares acquired before September 13, 2022 The investigation concerns misrepresentations to investors as to the true nature of the patient population that was being tested in Akero&#8217;s SYMMETRY study. Specifically, despite telling investors that the study&#8217;s patient population was limited to those with NASH induced cirrhosis (a fact that was key for data integrity and the likelihood of study success), for approximately 20% of those being tested Akero had not confirmed that the patients had NASH and that NASH had &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834748","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. (&#8220;Akero&#8221;) ( NASDAQ:AKRO ) Shareholders should email Fletcher@fmoorelaw.com; please contact only if shares acquired before September 13, 2022 The investigation concerns misrepresentations to investors as to the true nature of the patient population that was being tested in Akero&#8217;s SYMMETRY study. Specifically, despite telling investors that the study&#8217;s patient population was limited to those with NASH induced cirrhosis (a fact that was key for data integrity and the likelihood of study success), for approximately 20% of those being tested Akero had not confirmed that the patients had NASH and that NASH had &hellip; Continue reading &quot;INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T22:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm\",\"datePublished\":\"2025-04-07T22:46:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/\"},\"wordCount\":312,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/\",\"name\":\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=\",\"datePublished\":\"2025-04-07T22:46:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Market Newsdesk","og_description":"NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. (&#8220;Akero&#8221;) ( NASDAQ:AKRO ) Shareholders should email Fletcher@fmoorelaw.com; please contact only if shares acquired before September 13, 2022 The investigation concerns misrepresentations to investors as to the true nature of the patient population that was being tested in Akero&#8217;s SYMMETRY study. Specifically, despite telling investors that the study&#8217;s patient population was limited to those with NASH induced cirrhosis (a fact that was key for data integrity and the likelihood of study success), for approximately 20% of those being tested Akero had not confirmed that the patients had NASH and that NASH had &hellip; Continue reading \"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-07T22:46:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm","datePublished":"2025-04-07T22:46:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/"},"wordCount":312,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/","name":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=","datePublished":"2025-04-07T22:46:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODQxNCM2ODU1MjM3IzIyOTE0NjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834748"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834748\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}